ArriVent BioPharma Inc [AVBP] stock is trading at $25.42, up 9.24%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AVBP shares have gain 7.71% over the last week, with a monthly amount glided 32.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ArriVent BioPharma Inc [NASDAQ: AVBP] stock has seen the most recent analyst activity on March 20, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $37. Previously, Guggenheim started tracking the stock with Buy rating on March 10, 2025, and set its price target to $45. On July 22, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $35 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $25 on April 30, 2024. Jefferies initiated its recommendation with a Buy and recommended $35 as its price target on February 20, 2024. Goldman started tracking with a Buy rating for this stock on February 20, 2024, and assigned it a price target of $27. In a note dated February 20, 2024, Citigroup initiated an Buy rating and provided a target price of $30 on this stock.
ArriVent BioPharma Inc [AVBP] stock has fluctuated between $15.47 and $36.37 over the past year. Currently, Wall Street analysts expect the stock to reach $35.67 within the next 12 months. ArriVent BioPharma Inc [NASDAQ: AVBP] shares were valued at $25.42 at the most recent close of the market. An investor can expect a potential return of 40.32% based on the average AVBP price forecast.
Analyzing the AVBP fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -0.49 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.74 points at the first support level, and at 22.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.34, and for the 2nd resistance point, it is at 27.25.
Ratios To Look Out For
For context, ArriVent BioPharma Inc’s Current Ratio is 14.34. In addition, the Quick Ratio stands at 14.34 and the Cash Ratio stands at 3.85.
